Home>>Signaling Pathways>> GPCR/G protein>> Leukotriene Receptor>>LTD4 antagonist 1

LTD4 antagonist 1

Catalog No.GC31944

LTD4 antagonist 1 is a potent, orally active antagonist of leukotriene D4 (LTD4) with a Ki of 0.57 nM.

Products are for research use only. Not for human use. We do not sell to patients.

LTD4 antagonist 1 Chemical Structure

Cas No.: 136564-67-5

Size Price Stock Qty
1mg
$1,176.00
In stock
5mg
$2,354.00
In stock
10mg
$3,998.00
In stock
20mg
$7,060.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LTD4 antagonist 1 is a potent, orally active antagonist of leukotriene D4 (LTD4) with a Ki of 0.57 nM.

LTD4 antagonist 1 (Compound 38b) exhibits a Ki of 0.57 nM for displacement of [3H]LTD4 on guinea pig lung membranes, a pKB of 9.93±0.14 versus LTE4 on guinea pig trachea[1].

LTD4 antagonist 1 (Compound 38b) exhibits a po ED50/iv ED50 of 1.44 and 0.036 μmol/kg in LTD4-induced bronchoconstriction in guinea pigs[1].

[1]. Robert T. Jacobs, et al. Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4. Journal of Medicinal Chemistry (1994), 37(9), 1282-97.

Reviews

Review for LTD4 antagonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LTD4 antagonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.